What is the catalog number for Roxindole?

The catalog number for Roxindole is HY-106100.

What sizes are available for Roxindole?

Roxindole is available in the following size(s): 1 Each.

Is Roxindole in stock?

Roxindole is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Roxindole?

Roxindole is manufactured by QuantiMol.

What is the estimated delivery time for Roxindole?

Estimated delivery time for Roxindole is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Roxindole?

The safety data sheet for Roxindole is available here: http://file.medchemexpress.com/batch_PDF/HY-106100/.

Roxindole

Roxindole (EMD 49980), an indot-alkyl-pipenidine, is a potent agonist at dopamine autoreceptors, with an affinity for the D2-like subtype in the low nanomolar range. Roxindole can be used for the research of positive and negative schizophrenic symptoms. Roxindole is a 5-HT1A agonist and 5-HT uptake inhibitor. Antipsychotic and antidepressant activities[1][2][3].

Product Specifications

CAS Number

112192-04-8

Product Name Alternative

EMD 49980

UNSPSC

12352005

Target

Dopamine Receptor; Serotonin Transporter

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/roxindole.html

Solubility

10 mM in DMSO

Smiles

OC1=CC2=C(C=C1)NC=C2CCCCN3CCC(C4=CC=CC=C4)=CC3

Molecular Formula

C23H26N2O

Molecular Weight

346.47

References & Citations

[1]Bartoszyk GD, Harting J, Minck KO. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J Pharmacol Exp Ther. 1996;276 (1) :41-48.|[2]Wetzel H, et al. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry. 1994;151 (10) :1499-1502.|[3]Maj J, et al. Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. II. Effects on the 5-hydroxytryptamine system. Pharmacopsychiatry. 1997;30 (2) :55-61.|[4]Prehn JH, et al. Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Brain Res. 1993;630 (1-2) :10-20.